Sponsored by the National Institutes of Health (NINDS), the Clinical Proteomics Research Center (CPRC) explores the clinical applications of proteomic technology. The goals of the Clinical Proteomics Research Center are to explore neurovascular pathophysiology using a translational approach, to develop prognostic tools to guide clinical decision-making, and to discover new targets of therapeutic intervention at the bedside. Read more about CPRC research in the application of proteomic technology to clinical problem solving in neurovascular disease on our Research Project page.
MingMing Ning, MD
Scientific Advisory Board
Center Staff & Clinical Research Coordinators
The CPRC has four main areas of focus in the application of proteomic technology to clinical problem solving in neurovascular disease.
Clinical Proteomics Research on the Brain
For information about our ongoing clinical study--sponsored by the National Institute of Health (NIH/NINDS)-- called "Clinical Proteomics Research on the Brain" ("CPR" on the Brain), please contact Dr. Ning at email@example.com. "CPR" on the Brain is actively recruiting patients with acute and chronic history of stroke, neurovascular disease associated with patent forament ovale (PFO), and healthy subjects. More information can be found on http://clinicaltrials.gov/show/NCT00682331.
Public Transportation Access: yes
Disabled Access: yes
Mailcode: WACC 7-720
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Proto magazine stakes its ground on medicine's leading edge, reporting back from the frontiers of research and practice - exploring breakthroughs, dissecting controversies and opening a forum for informed debate.
Discover the largest hospital-based research program in the U.S. and how clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and bring the latest advances to patient care
Discover what makes Massachusetts General Hospital not just one of the best places to receive patient care but also one of the best places to work.